Biomed Central Ltd

SHERPA: Unknown

People

  1. Vickers
    Vickers
  2. Postow
    Postow
  3. D'Angelo
    D'Angelo
  4. Offit
    Offit
  5. Budhu
    Budhu
  6. Motzer
    Motzer
  7. Shoushtari
    Shoushtari
  8. Cheung
    Cheung
  9. Voss
    Voss
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (566)
  2. Solid Tumor Oncology Division (461)
  3. GSK Faculty (295)
  4. Sloan Kettering Institute Postdocs (194)
  5. Hematologic Malignancies, Division of (160)
  6. Population Sciences Research Program (158)
  7. Epidemiology and Biostatistics (153)
  8. Melanoma and Immunotherapeutics Service (148)
  9. Surgery (123)
  10. Survivorship Research (120)
Search Within
Formats
  1. Journal Article (751)
  2. Meeting Abstract (257)
  3. Review (40)
  4. Guidelines (20)
  5. Editorial (11)
  6. Research Letter (7)
  7. Correspondence (4)
  8. Conference Paper (1)
  9. Miscellaneous (1)
Groups
  1. Department of Medicine (566)
  2. Solid Tumor Oncology Division (461)
  3. GSK Faculty (295)
  4. Sloan Kettering Institute Postdocs (194)
  5. Hematologic Malignancies, Division of (160)
  6. Population Sciences Research Program (158)

More Groups

People
  1. Jedd Wolchok (83)
  2. Taha Merghoub (55)
  3. Andrew Vickers (44)
  4. Michael Postow (43)
  5. Matthew Hellmann (30)
  6. Sandra D'Angelo (26)

More People

Years
  1. 2025 (40)
  2. 2024 (60)
  3. 2023 (44)
  4. 2022 (122)
  5. 2021 (91)
  6. 2020 (99)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (412)
  2. Breast Cancer Research (67)
  3. BMC Cancer (65)
  4. Genome Biology (47)
  5. Journal of Hematology & Oncology (43)
  6. Journal of Translational Medicine (35)

More Publications

Results (1092)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Characterizing double positive T cells in the tumor microenvironment: A tale of promiscuous cell fates
    Meeting Abstract

    Schad, S.; Chow, A.; Pan, H.; Mangarin, L.; Zappasodi, R.; Gigoux, M.; Redmond, D.; Hirschhorn-Cymerman, D.; Budhu, S.; Zhong, H.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Updated clinical data from the melanoma expansion cohort of an ongoing ph1/1b study of eganelisib (formerly IPI-549) in combination with nivolumab
    Meeting Abstract

    Postow, M.; Sullivan, R.; Cohen, E.; Gutierrez, M.; Hong, D.; Steuer, C.; McCarter, J.; Zizlsperger, N.; Kutok, J.; O'Connell, B.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Radiotherapy and CTLA-4 blockade expand antitumor T cells differentiation states and cooperate with CD40 agonist to induce tumor rejection
    Meeting Abstract

    Rudqvist, N.; Lhuillier, C.; Charpentier, M.; Wennerberg, E.; Spada, S.; Sheridan, C.; Zhou, X. K.; Zhang, T.; Sims, J.; Alonso, A.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination
    Meeting Abstract

    Gigoux, M.; Zappasodi, R.; Park, J.; Pourpe, S.; Ghosh, A.; Bozkus, C. C.; Mangarin, L.; Redmond, D.; Verma, S.; Schad, S.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Safety and preliminary efficacy of intratumoral cavrotolimod (AST-008), a spherical nucleic acid TLR9 agonist, in combination with pembrolizumab in patients with advanced solid tumors
    Meeting Abstract

    O'Day, S.; Perez, C.; Wise-Draper, T.; Hanna, G.; Bhatia, S.; Kelly, C.; Medina, T.; Laux, D.; Daud, A.; Chandra, S.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • MK-3475-U02: Phase 1/2 study of investigational agents with or without pembrolizumab versus pembrolizumab monotherapy in melanoma
    Meeting Abstract

    Dummer, R.; Long, G. V.; Pavlick, A.; Postow, M.; Ribas, A.; Robert, C.; Scolyer, R. A.; Taube, J.; Tetzlaff, M.; Liao, J.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Interim analysis of phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (MBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIS)
    Meeting Abstract

    Lewis, K.; Peris, K.; Sekulic, A.; Stratigos, A.; Dunn, L.; Eroglu, Z.; Chang, A. L.; Migden, M.; Li, S.; Mohan, K.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Combining transcriptomic- and tissue-based immune biomarkers to evaluate GB1275, a CD11b modulator, as a single agent or with pembrolizumab in patients with advanced solid tumors
    Meeting Abstract

    Messersmith, W.; Rasco, D.; De Bono, J.; Wang-Gillam, A.; Park, W.; Nickle, D.; Galkin, A.; Ferguson, B.; Carter, L.; Zhou, L.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors
    Meeting Abstract

    Sharma, M.; Dumbrava, E. I.; Carvajal, R.; Catenacci, D.; Emens, L.; Hanna, G.; Juric, D.; Kang, Y. K.; Lee, J.; Lee, K. W.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • First-in-human phase 1/2a study of the novel nonfucosylated anti-CTLA-4 monoclonal antibody BMS-986218 +/- nivolumab in advanced solid tumors: Initial phase 1 results
    Meeting Abstract

    Friedman, C.; Ascierto, P.; Davar, D.; O'Hara, M.; Shapira-Frommer, R.; Dallos, M.; Khemka, V.; James, L.; Fischer, B.; Demes, S.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save